FDA Clearance Tracker · P250031
VENTANA PTEN (SP218) RxDx Assay
Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jun 12, 2026
Approved
Time to decision
298 days
Received Aug 18, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P250031
- Device name
- VENTANA PTEN (SP218) RxDx Assay
- Applicant location
- Tucson, AZ
- Received
- Aug 18, 2025
- Decided
- Jun 12, 2026
- Decision
- Approved
Device type
- Device type
- Immunohistochemistry Assay, Antibody (SHF)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
VENTANA PTEN (SP218) RxDx Assay is a qualitative immunohistochemical (IHC) assay using rabbit monoclonal anti-PTEN, clone SP218, intended for laboratory use in the assessment of phosphatase and tensin homolog (PTEN) protein in formalin-fixed paraffin-embedded (FFPE) prostatic adenocarcinoma tissue specimens by light microscopy. The assay is for use with OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument. The assay is indicated as a companion diagnostic to aid in identifying patients who may be eligible for treatment with TRUQAP (capivasertib) in combination with abiraterone acetate in accordance with the approved therapeutic product labeling. The clinical cutoff for PTEN Loss status is >=90% of viable malignant cells with no specific cytoplasmic staining.Test results should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls.This product is intended for in vitro diagnostic (IVD) use.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code SHF (Immunohistochemistry Assay, Antibody).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P240037 · Decided May 14, 2025 · 205 days after receipt
Device type: Immunohistochemistry Assay, Antibody, MET (SER) · Laboratory Medicine & Pathology
P210001 · Decided Aug 17, 2021 · 207 days after receipt
Device type: Immunohistochemistry test, DNA mismatch repair (MMR) Protein assay (QNH) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.